1. known hypersensitivity to omalizumab or its excipients 2. inability to give consent themselves or via proxy 3. patients who received omalizumab or another anti-ige molecule in the last 12 months 4. patients receiving another monoclonal antibody to treat sars-cov-2/other indication prior to starting ciao trial. however, once the study is initiated, if it is judged by the treating team/patient's doctor that patient's health/clinical status may benefit from a monoclonal antibody (e.g. tocilizumab), this will be allowed. 5. patients who are below the age of 18

1. known hypersensitivity to omalizumab or its excipients 2. inability to give consent themselves or via proxy 3. patients who received omalizumab or another anti-ige molecule in the last 12 months 4. patients receiving another monoclonal antibody to treat sars-cov-2/other indication prior to starting ciao trial. however, once the study is initiated, if it is judged by the treating team/patient's doctor that patient's health/clinical status may benefit from a monoclonal antibody (e.g. tocilizumab), this will be allowed. 5. patients who are below the age of 18

known hypersensitivity to omalizumab or its excipients inability to give consent themselves or via proxy patients who received omalizumab or another anti-ige molecule in the last 12 months patients receiving another monoclonal antibody to treat sars-cov-2/other indication prior to starting ciao trial. however, once the study is initiated, if it is judged by the treating team/patient's doctor that patient's health/clinical status may benefit from a monoclonal antibody (e.g. tocilizumab), this will be allowed. patients who are below the age of 18

known hypersensitivity to omalizumab or its excipients inability to give consent themselves or via proxy patients who received omalizumab or another anti-ige molecule in the last 12 months patients receiving another monoclonal antibody to treat sars-cov-2/other indication prior to starting ciao trial. however, once the study is initiated, if it is judged by the treating team/patient's doctor that patient's health/clinical status may benefit from a monoclonal antibody (e.g. tocilizumab), this will be allowed. patients who are below the age of 18

1. known hypersensitivity to omalizumab or its excipients 2. inability to give consent themselves or via proxy 3. patients who received omalizumab or another anti-ige molecule in the last 12 months 4. patients receiving another monoclonal antibody to treat sars-cov-2/other indication prior to starting ciao trial. however, once the study is initiated, if it is judged by the treating team/patient's doctor that patient's health/clinical status may benefit from a monoclonal antibody (e.g. tocilizumab), this will be allowed. 5. patients who are below the age of 18

1. known hypersensitivity to omalizumab or its excipients 2. inability to give consent themselves or via proxy 3. patients who received omalizumab or another anti-ige molecule in the last 12 months 4. patients receiving another monoclonal antibody to treat sars-cov-2/other indication prior to starting ciao trial. however, once the study is initiated, if it is judged by the treating team/patient's doctor that patient's health/clinical status may benefit from a monoclonal antibody (e.g. tocilizumab), this will be allowed. 5. patients who are below the age of 18

- known hypersensitivity to omalizumab or its excipients - inability to give consent (where appropriate and as approved by regional ethics boards, deferred consent will be an option for critically ill patients who are incapable and for whom a proxy cannot be located). - patients who received omalizumab or another anti-ige molecule in the last 12 months - patients receiving another monoclonal antibody to treat sars-cov-2/other indication - patients who are below the age of 18

- known hypersensitivity to omalizumab or its excipients - inability to give consent (where appropriate and as approved by regional ethics boards, deferred consent will be an option for critically ill patients who are incapable and for whom a proxy cannot be located). - patients who received omalizumab or another anti-ige molecule in the last 12 months - patients receiving another monoclonal antibody to treat sars-cov-2/other indication - patients who are below the age of 18